Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00145847 · ClinicalTrials.gov registry record · Phase 4
Naltrexone Treatment of Alcohol Abuse in Schizophrenia
A Phase 4 study of Schizophrenia and Alcoholism, sponsored by State University of New York - Upstate Medical University.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
- 4
- Study locations
NCT00145847 is a Phase 4 study of Schizophrenia and Alcoholism that has completed, run by State University of New York - Upstate Medical University. The registered enrollment target is 90 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (59% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT00145847, a Phase 4 study of Schizophrenia and Alcoholism, has completed, sponsored by State University of New York - Upstate Medical University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary purpose of this study is to determine whether naltrexone is effective in the treatment of alcohol dependence and abuse in patients with schizophrenia and schizoaffective disorder. Hypotheses are as follows: hypothesis 1: Naltrexone will be more effective than placebo in reducing alcohol use. hypothesis 2: Patients responding to naltrexone by reducing alcohol use will also show reductions in severity of psychiatric symptoms and utilization of inpatient and emergency psychiatric services. hypothesis 3: Severity of psychiatric symptoms and amount of service utilization will correlate positively with alcohol use.
Conditions Studied
Interventions
- DRUG Naltrexone or Placebo
Study Locations (4)
New York
- St. Joseph's Mental Health Services - Syracuse
- Hutchings Psychiatric Center - Syracuse
- SUNY Upstate Medical University - Syracuse
- Veterans Administration Healthcare Center - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2003-04 |
| Est. Completion | 2008-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00145847
The ClinicalTrials.gov registry entry for NCT00145847 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (59% lower). The listed sponsor is State University of New York - Upstate Medical University, which has 113 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Naltrexone or Placebo is the first listed.
NCT00145847 reports 4 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00145847 about?
NCT00145847 is a clinical study titled "Naltrexone Treatment of Alcohol Abuse in Schizophrenia". The primary purpose of this study is to determine whether naltrexone is effective in the treatment of alcohol dependence and abuse in patients with schizophrenia and schizoaffective disorder. Hypotheses are as follows: hypothesis 1: Naltrexone will be more effective than placebo in reducing alcohol...
What is the current status of trial NCT00145847?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2003-04. Estimated completion is 2008-05.
What conditions does trial NCT00145847 study?
This clinical trial studies the following conditions: Schizophrenia, Alcoholism, Alcohol Abuse, Mental Disorders, Alcohol-Related Disorders.
What interventions are being tested in trial NCT00145847?
The interventions under investigation include: Naltrexone or Placebo (DRUG).
Who is sponsoring clinical trial NCT00145847?
This trial is sponsored by State University of New York - Upstate Medical University, which has 113 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00145847 being conducted?
This trial has 4 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
CLOZAPINE Response in Biotype-1
RECRUITING · Phase 4
-
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
RECRUITING · Phase 4
-
Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
RECRUITING · Phase 4
-
Anti-Inflammatory Challenge in Schizophrenia
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.